source
- Tolerance Bio secures up to $260 M for thymus‑targeting fusion protein, moves into Phase 2 trialsTolerance Bio, a Philadelphia biotech founded in October 2024, has signed a licensing agreement to acquire rights to NeoImmuneTech’s long‑acting IL‑7 fusion protein, efineptakin alfa, for up to $26…
- Merck and Moderna’s personalized mRNA vaccine shows longer recurrence-free survival in phase 3 melanoma trialMerck and Moderna reported that their individualized mRNA cancer vaccine, given together with Keytruda, extended the time patients remained free of melanoma recurrence in a late-stage study. The p…Fierce Biotech · 1d agoPositive readoutPositive